Thymoquinone / Akt Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱
Features: Anti-oxidant, anti-tumor
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Label Primary Effect Notes / Cancer Relevance Ref
1 Reactive oxygen species (ROS) ↑ ROS Driver Upstream cytotoxic trigger Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts (ref)
2 Glutathione (GSH) redox buffering ↓ GSH Driver Redox-collapse amplification Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Driver Mitochondrial dysfunction (MOMP axis) Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death) (ref)
4 Intrinsic apoptosis (caspase-9 → caspase-3; PARP) ↑ caspases / ↑ apoptosis Driver Execution-phase cell death Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway (ref)
5 NF-κB signaling ↓ NF-κB activity Secondary Reduced pro-survival / inflammatory transcription Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support) (ref)
6 STAT3 signaling ↓ p-STAT3 / ↓ STAT3 activation Secondary Reduced survival/proliferation signaling Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts (ref)
7 NRF2 antioxidant-response axis (NRF2/HO-1 program) ↑ NRF2 pathway (often as stress-response) Adaptive Cellular antioxidant counter-response In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress (ref)
8 HIF-1α hypoxia signaling ↓ HIF-1α protein / ↓ HIF-1α program Adaptive Loss of hypoxia survival signaling Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia (ref)
9 Glycolysis / Warburg output (hypoxia-linked) ↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism) Phenotypic Metabolic suppression In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation (ref)  |  (ref)


Akt, PKB-Protein kinase B: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport.

Inhibitors:
-Curcumin: downregulate AKT phosphorylation and signaling.
-Resveratrol
-Quercetin: inhibit the PI3K/AKT pathway.
-Epigallocatechin Gallate (EGCG)
-Luteolin and Apigenin: inhibit AKT phosphorylation


Scientific Papers found: Click to Expand⟱
4774- 5-FU,  TQ,  CoQ10,    Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation
- in-vitro, CRC, NA
AntiCan↑, TumCCA↑, Apoptosis↑, eff↑, Bcl-2↓, survivin↓, P21↑, p27↑, BAX↑, Cyt‑c↑, Casp3↑, PI3K↓, Akt↓, mTOR↓, Hif1a↓, PTEN↑, AMPKα↑, PDH↑, LDHA↓, antiOx↓, ROS↑, AntiCan↑,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
2135- TQ,    Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets
- in-vitro, Nor, HaCaT
*HO-1↑, *NRF2↑, *e-ERK↑, *e-Akt↑, *AMPKα↑, *ROS⇅, *eff↓, *tumCV∅,
3573- TQ,    Chronic diseases, inflammation, and spices: how are they linked?
- Review, Var, NA
NF-kB↓, XIAP↓, PI3K↓, Akt↓, STAT3↓, JAK2↓, cSrc↓, PCNA↓, MMP2↓, ERK↓, Ki-67↓, Bcl-2↓, VEGF↓, p65↓, COX2↓, MMP9↓,
4565- TQ,    Thymoquinone in the clinical treatment of cancer: Fact or fiction?
- Review, BC, NA
Dose↝, TumCCA↑, P21↑, cycD1/CCND1↓, TumCI↑, TumMeta↓, Bcl-2↓, Bcl-xL↓, survivin↓, PTEN↑, Akt↓, P53↑, NF-kB↓, cardioP↑, Dose↝,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
3555- TQ,    Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta1-42 infused rat model
- in-vivo, AD, NA
*memory↑, *BAX↓, *Aβ↓, *p‑tau↓, *AChE↓, *p‑Akt↓, *Ach↑, *Inflam↓,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
2085- TQ,    Anticancer Activities of Nigella Sativa (Black Cumin)
- Review, Var, NA
MMP↓, Casp3↑, Casp8↑, Casp9↓, cl‑PARP↑, Cyt‑c↑, Bax:Bcl2↑, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, cJun↑, p38↑, Akt↑, chemoP↑, *radioP↑,
1019- TQ,    Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation
- vitro+vivo, CRC, LoVo
TumCP↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, β-catenin/ZEB1↓, COX2↓, PGE2↓, EP2↓, EP4↓,
1935- TQ,    Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis
- Review, OS, NA
Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, ROS↑, P53↑, Twist↓, E-cadherin↑, N-cadherin↓, NF-kB↓, IL8↓, XIAP↓, Bcl-2↓, STAT3↓, MAPK↓, PI3K↓, Akt↓, ERK↓, MMP2↓, MMP9↓, *ROS↓, HO-1↑, selectivity↑, TumCG↓,
2123- TQ,    Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma
- in-vitro, lymphoma, PEL
Akt↓, ROS↑, BAX↓, MMP↓, Cyt‑c↑, eff↑, Casp9↑, Casp3↑, cl‑PARP↑, DR5↑,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2128- TQ,    Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo
- in-vivo, NA, NA
*COX2↓, *NF-kB↓, *p‑Akt↓, *p‑cJun↓, *p‑p38↓, *HO-1↑, *NADPH↑, *GSTA1↑, *antiOx↑, *Inflam↓, *NQO1↑, *GCLC↑, *GSTA1↑,
2129- TQ,  doxoR,    Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
- in-vitro, BC, MCF-7
ChemoSen↑, PTEN↑, p‑Akt↓, TumCCA↑, P53↑, P21↑, Apoptosis↑, MMP↓, Casp↑, cl‑PARP↑, Bax:Bcl2↑, eff↓, DNAdam↓, p‑γH2AX↑, ROS↑,
2133- TQ,  CUR,  Cisplatin,    Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling
- in-vitro, Nor, HEK293 - in-vivo, NA, NA
*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,

Showing Research Papers: 1 to 24 of 24

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   GSH↓, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↑, 12,   ROS⇅, 4,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 4,   Raf↓, 1,   XIAP↓, 7,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 3,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   NADPH↓, 1,   PDH↑, 1,   PKM2↓, 2,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 13,   Akt↑, 2,   p‑Akt↓, 6,   Apoptosis↑, 9,   Bak↑, 1,   BAX↓, 1,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 10,   Bcl-2↑, 1,   Bcl-xL↓, 5,   BID↓, 1,   Casp↑, 3,   Casp3↑, 7,   Casp7↑, 2,   Casp8↑, 2,   Casp9↓, 1,   Casp9↑, 5,   Cyt‑c↑, 5,   DR5↑, 2,   Fas↑, 1,   IAP1↓, 2,   IAP2↓, 1,   IAP2↑, 1,   iNOS↓, 1,   JNK↑, 3,   MAPK↓, 2,   MAPK↑, 3,   p‑MAPK↑, 1,   Mcl-1↓, 2,   Myc↓, 1,   p27↑, 4,   p38↑, 4,   p‑p38↑, 1,   survivin↓, 8,   Telomerase↓, 1,   TRAIL↑, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 2,   cSrc↓, 2,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   EZH2↓, 1,   H4↑, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↓, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   CYP1B1↑, 1,   DNAdam↓, 1,   DNAdam↑, 1,   DNMT1↓, 4,   DNMT3A↓, 1,   p16↑, 1,   P53↑, 8,   cl‑PARP↑, 7,   PCNA↓, 1,   UHRF1↓, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 6,   E2Fs↓, 1,   P21↑, 6,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

CD34↓, 1,   cMET↓, 1,   EMT↓, 6,   EP2↓, 1,   EP4↓, 1,   ERK↓, 7,   ERK↑, 1,   p‑ERK↓, 1,   FOXO↑, 1,   GSK‐3β↓, 2,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 4,   HDAC1↓, 3,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   Jun↓, 1,   miR-34a↑, 1,   mTOR↓, 7,   p‑mTOR↓, 1,   NOTCH↓, 3,   P70S6K↓, 1,   PI3K↓, 12,   PI3K↑, 1,   p‑PI3K↓, 2,   PTEN↑, 9,   RAS↓, 1,   STAT3↓, 5,   p‑STAT3↓, 3,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 1,   DLC1↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   FAK↓, 2,   ITGA5↓, 1,   Ki-67↓, 3,   MET↓, 1,   MMP2↓, 4,   MMP7↓, 2,   MMP9↓, 6,   MMPs↓, 2,   MUC4↓, 2,   N-cadherin↓, 4,   Rac1↓, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TGF-β↑, 1,   TumCI↓, 3,   TumCI↑, 1,   TumCMig↓, 2,   TumCP↓, 5,   TumMeta↓, 5,   Twist↓, 8,   Vim↓, 2,   Zeb1↓, 4,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   angioG↑, 1,   Hif1a↓, 2,   VEGF↓, 7,   VEGFR2↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 7,   CXCL1↓, 1,   CXCR4↓, 3,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL2↑, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 3,   IκB↓, 1,   JAK2↓, 4,   MCP1↓, 1,   NF-kB↓, 10,   p‑NF-kB↑, 1,   NK cell↑, 1,   p65↓, 3,   p‑p65↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 8,   Dose↝, 4,   eff↓, 2,   eff↑, 8,   RadioS↑, 4,   selectivity↑, 5,   TET2↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   BRCA1↑, 1,   EZH2↓, 1,   IL6↓, 1,   Ki-67↓, 3,   Maspin↑, 1,   Myc↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 4,   cardioP↑, 1,   chemoP↑, 3,   chemoPv↑, 1,   hepatoP↑, 2,   RenoP↑, 1,  
Total Targets: 207

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 4,   GCLC↑, 1,   GPx↑, 4,   GSH↑, 3,   GSR↑, 1,   GSTA1↓, 1,   GSTA1↑, 3,   GSTs↑, 1,   H2O2↓, 2,   HO-1↑, 4,   lipid-P↓, 2,   MDA↓, 2,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 5,   ROS⇅, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   LDH↓, 1,   NAD↑, 1,   NADPH↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

p‑Akt↓, 2,   p‑Akt↑, 1,   e-Akt↑, 1,   BAX↓, 2,   Casp3↓, 2,   iNOS↑, 1,   JNK↑, 1,   MAPK↑, 1,   p‑p38↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   p‑cJun↓, 1,   tumCV∅, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

e-ERK↑, 1,  

Migration ⓘ

mt-ATPase↑, 1,   MMP13↓, 2,   MMP9↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

MRP↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CRP↓, 2,   IL10↑, 1,   IL12↓, 1,   IL1β↓, 4,   IL6↓, 3,   Inflam↓, 5,   MyD88↓, 1,   NF-kB↓, 3,   PGE2↓, 2,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 3,   TRIF↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 3,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Hormonal & Nuclear Receptors ⓘ

GR↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↝, 2,   eff↓, 1,   eff↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

creat↓, 1,   CRP↓, 2,   IL6↓, 3,   LDH↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   GFR↑, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 1,   radioP↑, 2,   RenoP↑, 3,  

Infection & Microbiome ⓘ

IRF3↓, 1,  
Total Targets: 85

Scientific Paper Hit Count for: Akt, PKB-Protein kinase B
24 Thymoquinone
1 5-fluorouracil
1 Coenzyme Q10
1 doxorubicin
1 Curcumin
1 Cisplatin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:4  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page